Author:
Kubasch Anne Sophie,Platzbecker Uwe
Reference10 articles.
1. Fenaux P Mufti GJ Hellstrom-Lindberg E, et al. International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol, 2009 Mar; 10(3): 223–232.
2. Greenberg PL, Tüchler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 2012; 120: 2454–2465.
3. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul;36(7): 1703–1719.
4. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med, 2005; 352: 549–557.
5. Platzbecker U. Treatment of MDS. Blood, 2019; 133(10): 1096–1107.